BCG vaccine immunity against human tuberculosis. The BCG vaccine can be anywhere from 0 to 80% effective in preventing tuberculosis for a duration of 15 years; however, its protective effect appears to vary according to geography and the lab in which the vaccine strain was grown. A number of different companies make BCG, sometimes using different genetic strains of the bacterium. This may result in different product characteristics. OncoTICE, used for bladder instillation for bladder cancer, was developed by Organon Laboratories (since acquired by Schering-Plough, and in turn acquired by Merck & Co.). Pacis BCG, made from the Montréal (Institut Armand-Frappier) strain,
Inoculation theory opinion. These contexts include: politics (e.g., Pfau et al., 1990; see Compton & Ivanov, 2013, for a review), health campaigns (e.g., Pfau & VanBockern, 1994; see Compton, Jackson, & Dimmock, 2016, for a review), marketing (e.g., Compton & Pfau, 2004) and education (Compton, 2011), among others. (See Banas & Rains, 2010, for a meta-analysis, and Compton, 2013, for a narrative overview.) The inoculation process is analogous to the medical inoculation process from which it draws its name; the analogy served as the inaugural exemplar for how inoculation confers resistance. As McGuire (1961) initially explained, medical inoculation works by exposing the